TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women’s healthcare company ("TherapeuticsMD" or the "Company"), announced today the appointment of Joel S. Krasnow, M.D., M.B.A., a leading board-certified OB/GYN and reproductive endocrinologist with broad biotech and pharmaceutical experience, as the Company's Chief Scientific Officer and head of its regulatory department.
Dr. Krasnow’s career spans 15 years in the pharmaceutical industry, including several global product registrations in women’s health and related areas. He began his career in academic medicine where he received funding for both basic science and clinical research in women’s health. During his time in academic medicine, Dr. Krasnow served as the Principal Investigator on a number of menopause clinical trials involving investigational hormone therapy (HT) regimens, two of which involved Premarin ® and Provera ®. He also acted as the Co-Investigator of a study on the endometrial histological effects of Prometrium ®. He is widely published, with more than 20 papers in the women’s health field, and has actively participated in trial activities related to numerous grants. His industry experience comprises a broad spectrum of specialties including contraception, HT, reproductive medicine, endocrinology, immunology, urology and gastroenterology. Dr. Krasnow has participated in and directed many IND/NDA/BLA filings, presentations and labeling negotiations resulting in numerous regulatory approvals across therapeutic areas, and has managed clinical and medical marketing programs in women’s health including VagiFem ® (vaginal atrophy secondary to menopause) and Activella ® (HT).
"We are pleased to welcome Dr. Krasnow to TherapeuticsMD. His hands-on experience with and oversight of the product approval process for both VagiFem and Activella are directly relevant to our strategic path going forward, and will be a real asset as we seek to introduce innovative treatment products in the women’s hormone and health market. With his vast experience in clinical trials design and management, medical affairs, drug safety and pharmacovigilance, and regulatory interactions, especially with the U.S. Food and Drug Administration (FDA), Dr. Krasnow’s contributions will be invaluable as we execute late stage clinical trials for our novel hormone therapy (HT) product candidates including our bioidentical oral E+P combination HT product, our low-dose progesterone candidate for secondary amenorrhea, and estradiol VagiCap for vulvar and vaginal atrophy," said Robert G. Finizio, Co-Founder and Chief Executive Officer of TherapeuticsMD.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts